Traders should monitor for selling activity by the named shareholders, which could increase near-term supply and pressure on the stock price. The lack of proceeds to the company reduces capital risk but increases shareholder dilution risk if sales are significant.
Price Chart
Executive Summary
Cellyan Biotechnology's F-1 registration statement has become effective, allowing the resale of up to 12.5 million Class A ordinary shares by selling shareholders. This is not a capital raise for the company, and it follows the company's recent name change from Hong Kong Pharma Digital Technology Holdings Ltd.
Key Facts
- The F-1 registration statement became effective on April 8, 2026, permitting resale of up to 12,499,986 Class A ordinary shares by selling shareholders.
- Cellyan Biotechnology will not receive any proceeds from the sales; all shares were issued in a private placement on March 25, 2026.
- The company trades on Nasdaq under ticker HKPD, with a market cap of $12M and a recent share price of $0.65.
- The company is a 'controlled company' with Ms. Liying Wang holding approximately 95.63% of voting power via Class B shares.
- This is not an IPO but a registration for resales of previously issued shares, following an F-1 filing on March 27, 2026.
Financial Impact
No direct financial impact to the company as it does not receive proceeds. However, potential share price pressure from up to $8.1 million in aggregate resale value (12.5M shares × $0.65).
Risk Factors
- Potential for near-term share price volatility due to selling by registered shareholders.
- Concentration of control with Ms. Liying Wang limits corporate governance protections for public shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001120 |
| Document: 9999999995-26-001120-index.html | 9999999995-26-001120 |
| Document: 9999999995-26-001120.txt | 9999999995-26-001120 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $0.1020 $0.0960 | ▲ +5.88% | ▲ +4.70% | $2.24 (−2094.31%) |
Sep 23, 2026 4w ago | 6-K | $0.1207 $0.1118 | ▼ −7.37% | ▼ −7.92% | $2.24 (+1754.35%) |
Sep 23, 2026 4w ago | 6-K | $0.1192 $0.1207 | ▲ +1.26% | ▲ +1.34% | $2.24 (+1777.68%) |
Jun 25, 2026 17w ago | EFFECT | $0.3710 $0.3610 | ▲ +2.70% | ▲ +1.97% | $2.24 (−503.29%) |
Apr 9, 2026 28w ago | EFFECT | $0.5570 $0.6220 | ▲ +11.67% | ▲ +11.73% | $2.24 (+301.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers